Aus Clinical Evidence Guidance Tackles 'Leading Cause' Of Medtech Rejections
This article was originally published in Clinica
Australia's Therapeutic Goods Administration is seeking to clarify for medical device makers its expectations for clinical evidence, the inadequacy of which has apparently been a leading cause of rejection of registration applications in the country, especially for higher risk devices.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.